

SuperGen, Inc.

BIO Member, Presenting Company

Clinical Foci: Oncology • Drug Discovery • Drug Development



James S.J. Manuso, PhD
Chief Executive Officer
 4140 Dublin Blvd., Suite 200
 Dublin, CA 94568
 USA

www.supergen.com
 1-925-560-0100

NASDAQ Stock Market: SUPG
Incorporated: 1991
Employees: 90
Ownership: Public

HIGHLIGHTS

Recent

SGL-110 Phase 1 trial began in 1Q11 and has both weekly and 5 day dosing to evaluate scheduling.
 Amuvatinib (MP-470) has been cleared for Phase 2 trial in SCLC with Etoposide / platinum combinations.

Upcoming

Amuvatinib (MP-470) Initiate Phase 2 trial 1H11.
 Dacogen AML filings in the US & EU 2011.

CORPORATE MISSION

SuperGen, Inc. is a pharmaceutical company dedicated to the discovery and development of novel cancer therapies. Headquartered in Northern California, with discovery operations in Salt Lake City, Utah, SuperGen focuses on therapeutics in epigenetic and cell signaling modulation. SuperGen develops products through biochemical and clinical proof of concept to partner for further development and commercialization. The company receives royalty revenue from Dacogen® (decitabine) partnerships with Eisai Co., Ltd. and Johnson & Johnson. For more information, please visit www.supergen.com.

PROPRIETARY TECHNOLOGY

SuperGen's drug discovery process, CLIMB®, merges computational screening of reference compound libraries with systems biology to create drug leads with favorable pharmaceutical properties. Our current drug programs target multiple kinases (such as PIM, AXL, mutant KIT, and PDGFRα), methyltransferase (e.g. DNMT1) and cell cycle checkpoints (e.g. PIM1, MDM2). MP-470, our multi-targeted TKI and DNA repair suppressor, is currently in entering Phase 2 clinical trials in SCLC. SGL-110, our DNMT-1 inhibitor, is in Phase 1 trials for MDS & AML.

CORPORATE ALLIANCES

SuperGen has developed and licensed for commercialization Dacogen® (decitabine for injection), Nipent® (pentostatin for injection) and other oncology products.

PRODUCTS

Name	Indication	Phase	Milestone
Amuvatinib (MP-470) - Multi-targeted TKI & DNA Repair Suppressor	Oncology	Phase II, IIa, IIb	Initiate Phase 2 - 1H11
SGL-110 DNMT 1 Inhibitor	MDS & AML with potential in Solid Tumors	Phase I	

SENIOR MANAGEMENT


James S.J. Manuso, PhD, Chief Executive Officer • **Mohammad Azab, MD**, Chief Medical Officer • **Michael Molkentin, CPA**, Chief Financial Officer • **Timothy L. Enns**, Senior Vice President • **Gavin Choy, PharmD**, Vice President • **Shu Lee, PhD**, Vice President • **Michael V. McCullar, PhD**, Senior Vice President • **Sanjeev Redkar, PhD**, Vice President • **David S. Smith, PhD**, Vice President

BOARD OF DIRECTORS

James S. J. Manuso, PhD, SuperGen, Inc. • **Charles J. Casamento**, The Sage Group, Inc. • **Thomas V. Girardi**, Girardi & Keese • **Allan R. Goldberg, PhD**, The Channel Group, LLC • **Walter J. Lack**, Engstrom, Lipscomb & Lack • **Michael D. Young, MD, PhD**, Strategic Healthcare Development, LLC

SCIENTIFIC ADVISORY BOARD

John Crowley, PhD, CEO, Cancer Research and Biostatistics (CRAB); Director, Southwest Oncology Group Statistical Ctr. • **Stephen Baylin, MD**, Prof of Oncology, Johns Hopkins Sch of Medicine; Chair, Epigenetics Dream Team, Stand Up To Cancer • **Michele Maio, MD, PhD**, Chairman, Dept. of Medical Oncology & Immunotherapy, University Hospital of Siena • **Hagop Kantarjian, MD**, Prof. & Chairman of Dept. of Leukemia, U.T. MD Anderson Cancer Center • **Fred Appelbaum, MD**, Leukemia Committee Chair, Southwest Oncology Grp; Fred Hutchinson Cancer Research Center • **Thomas Lynch, MD**, Physician-in-Chief, Smilow Cancer Hospital; Director, Yale Comprehensive Cancer Center • **Daniel D. Von Hoff, MD, FACP**, Physician-in-Chief & Director, Translational Genomics Research Institute (TGEN) • **Anthony Tolcher, MD**, Director, Clinical Research, START Clinical Research



Market Data

Current Price	2.89
Currency	US Dollar
Net Change	-0.69
Volume.....	373,372
YTD % Change	0.10
52Wk Range	1.71-3.80
Avg. Daily Volume (thousands).....	344,700

First Call Data

Market Cap (MM)	174.3
Short Interest Shares.....	2,505,769
Short Interest Ratio.....	7.57
PE (Trailing 12 Months)	0.13
EPS (Last Fiscal Year)	0.20
Consensus Estimate (Y)	0.13
Consensus Recommend	0.13
Price/Sales	3.52

Shareholders

<i>Institution</i>	<i>Holding %</i>
BVF, Inc.	9.8%
BlackRock Fund Advisors	5.5%
Wellington Management Co. LLP	3.9%
OrbiMed Advisors, Inc.	3.8%
State of Wisconsin Investment Board.....	2.5%
<i>Mutual Fund</i>	<i>Holding %</i>
BVF, Inc.	9.8%
BlackRock Fund Advisors	5.5%
Wellington Management Co. LLP	3.9%
OrbiMed Advisors, Inc.	3.8%
State of Wisconsin Investment Board.....	2.5%

Source: Thomson Reuters